Tina leads transformation programs with life sciences companies in China across multinational corporations (MNCs) and local corporations. She has extensive experience helping pharmaceutical companies drive performance improvements across R&D, business development, manufacturing, and commercial excellence domains. She also leads many digital transformation programs with life sciences companies in Greater China.
Tina has coauthored several white papers on China’s healthcare market, including “In search of new business models for Big Pharma in China” and “Building bridges to innovation” for Biocentury’s China Healthcare Summit (2013–2024).
Tina was nominated by Fortune China as one of the “Most Powerful Women” in 2023 and was included on the Forbes China list of 100 outstanding overseas returnees in 2024.